Mentoring in patient-oriented atrial fibrillation and cardiovascular research

项目摘要 本申请将为主要研究者Alvaro Alonso博士提供受保护的时间和其他支持 （1）加快指导初级临床研究者和研究生的成功记录 在以患者为导向的心血管研究中;（2）获得组学，机器学习和 指导最佳实践;（3）推进阿隆索博士正在进行的关于风险因素和机制的研究 导致心房颤动（AF）的发展。指导活动将建立在正在进行的 阿隆索博士参与埃默里大学的几个培训项目，包括一个由NHLBI资助的 关于心血管健康差异的多学科T32培训补助金，研究跟踪心脏病学 医学院的奖学金计划，以及公共卫生硕士和博士课程， 罗林斯公共卫生学院的流行病学。培训将侧重于以下方面的前沿方法领域： 快速发展，包括将组学技术和机器学习整合到以患者为导向的 研究，以及在学术，研究和临床指导技能的收购。最后，该奖项将 支持一个研究项目，该项目扩展了阿隆索博士正在进行的关于了解影响 AF底物的发展，了解AF病理生理学，预防AF相关结局。 本研究的具体目的是：（1）使用广泛的方法鉴定新的AF表型（表型组）， 临床和多组学数据（“现象图谱”），（2）发现不同AF的特定风险因素 表型组，以及（3）确定AF表型组与选定终点（中风、心脏病）的相关性 失败、死亡）。这些研究目标将在埃默里心血管生物库的背景下进行， 一项正在进行的前瞻性登记研究，对在三个埃默里附属医院接受心导管插入术的患者进行了登记。 医院目前包括大约7,000个具有详细表型、临床 结果和多组学标记。总之，本申请中提出的活动将有利地影响 博士Alonso在心血管领域进行尖端和创新的以患者为导向的研究的能力 预防和他的能力，作为一个高素质的导师，初级临床医生追求的研究， 临床心血管流行病学和预防。

PROJECT SUMMARY This application will provide the Principal Investigator, Dr. Alvaro Alonso, with protected time and other support to (1) accelerate a successful record of mentoring junior clinical investigators and graduate students engaged in patient-oriented cardiovascular research; (2) obtain additional training in omics, machine learning, and mentoring best-practices; and (3) advance Dr. Alonso's ongoing research on the risk factors and mechanisms contributing to the development of atrial fibrillation (AF). Mentoring activities will build upon the ongoing involvement of Dr. Alonso in several training programs at Emory University, including an NHLBI-funded multidisciplinary T32 training grant on cardiovascular health disparities, the research-track Cardiology fellowship program at the School of Medicine, and the Master of Public Health and PhD programs in epidemiology at the Rollins School of Public Health. Training will focus on cutting-edge methodological areas in rapid development, including integration of omic technologies and machine learning in patient-oriented research, as well as acquisition of skills in academic, research, and clinical mentoring. Finally, this award will support a research project that extends Dr. Alonso's ongoing work on understanding the factors influencing the development of the AF substrate, understanding AF pathophysiology, and preventing AF-related outcomes. The specific aims of this research are: (1) to identify novel AF phenotypes (phenogroups) using extensive clinical and multi-omic data (“phenomapping”), (2) to discover specific risk factors for the different AF phenogroups, and (3) to determine associations of AF phenogroups with selected endpoints (stroke, heart failure, mortality). These research aims will be carried out in the context of the Emory Cardiovascular Biobank, an ongoing prospective registry of patients undergoing cardiac catheterization in three Emory-affiliated hospitals currently including approximately 7,000 unique individuals with detailed phenotyping, clinical outcomes, and multi-omic markers. In summary, the activities proposed in this application will favorably impact Dr. Alonso's capabilities to conduct cutting-edge and innovative patient-oriented research on cardiovascular prevention and his ability to perform as a highly qualified mentor for junior clinicians pursuing research on clinical cardiovascular epidemiology and prevention.